News & Events - Inventiva Pharma

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

27 October 2021

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

20 October 2021

Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

18 October 2021

Inventiva announces participation at several investor conferences in October 2021

28 September 2021

Upcoming Investors Meetings

Upcoming Science Conferences

International Conference on Fatty liver

From 17th to 19th February 2022

Vienna, Austria

Questions?
Get in touch!

Inventiva
Pascaline Clerc
VP Global External Affairs
pascaline.clerc@inventivapharma.com
+1 240 620 9175

Brunswick
Laurence Frost / Tristan Roquet Montegon / Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_173436417_1	1 Jour/s	Ces cookies sont utilisés pour collecter des informations sur la façon dont les visiteurs utilisent notre site Web. Ceci est unique au propriétaire du site Web
_gat_gtag_UA_55628332_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
43410	session	No description available.
43411	session	No description
bm_mi	session	No description available.
DrupalVisitorMobile	session	No description available.
GZIP	5 years	No description available.

Cookie	Duration	Description
ak_bmsc	2 hours	This cookie is used by Akamai to optimize site security by distinguishing between humans and bots
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

Inventiva reports 2021 Third Quarter Financial Information

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

Inventiva announces participation at several investor conferences in November 2021

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

Inventiva announces participation at several investor conferences in October 2021

Upcoming Investors Meetings

Upcoming Science Conferences

International Conference on Fatty liver

Questions?
Get in touch!

About Inventiva

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

Inventiva reports 2021 Third Quarter Financial Information

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

Inventiva announces participation at several investor conferences in November 2021

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

Inventiva announces participation at several investor conferences in October 2021

Upcoming Investors Meetings

Upcoming Science Conferences

International Conference on Fatty liver

Questions?Get in touch!

Questions?
Get in touch!